Osavampator
Overview of the drug Osavampator
| Osavampator | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Osavampator (development code TAK-653) is a pharmaceutical drug that acts as a positive allosteric modulator of the AMPA receptor. It is being investigated for its potential use in the treatment of major depressive disorder and other neurological disorders.
Mechanism of Action[edit | edit source]
Osavampator functions as a positive allosteric modulator of the AMPA receptor, which is a subtype of the glutamate receptors in the central nervous system. By enhancing the activity of these receptors, Osavampator may increase synaptic transmission and neuroplasticity, potentially leading to improved cognitive function and mood regulation.
Pharmacology[edit | edit source]
Osavampator is designed to selectively modulate the AMPA receptors without directly activating them. This selectivity is crucial as it allows for the enhancement of synaptic responses to endogenous glutamate without causing excessive excitotoxicity, which can occur with direct agonists.
Clinical Development[edit | edit source]
Osavampator is currently in the clinical trial phase, with studies focusing on its efficacy and safety in treating major depressive disorder. The drug is being evaluated for its potential to provide rapid antidepressant effects, similar to those observed with other AMPA receptor modulators.
Potential Applications[edit | edit source]
Beyond its use in major depressive disorder, Osavampator is being explored for its potential benefits in other conditions such as schizophrenia, bipolar disorder, and cognitive impairment associated with neurodegenerative diseases.
Safety and Tolerability[edit | edit source]
The safety profile of Osavampator is still under investigation. Early clinical trials suggest that it is generally well-tolerated, with a side effect profile similar to other drugs in its class. Common side effects may include headache, nausea, and dizziness.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
